| Autor: |
Avdeev SN; Sechenov First Moscow State Medical University (Sechenov University)., Chulanov VP; Sechenov First Moscow State Medical University (Sechenov University).; National Medical Research Center for Phthisiopulmonology and Infectious Diseases., Alexeeva EI; Sechenov First Moscow State Medical University (Sechenov University).; National Medical Research Center for Children's Health., Aleshina OA; National Medical Research Center for Hematology., Bereznikov AV; AlfaStrakhovanie-OMS LLC.; ROSBIOTECH University., Kotenko ON; City Clinical Hospital №52.; Pirogov Russian National Research Medical University., Lila AM; Nasonova Research Institute of Rheumatology.; Russian Medical Academy of Continuous Professional Education., Mutovina ZY; City Clinical Hospital №52.; Central State Medical Academy of the Administrative Department of the President of the Russian Federation., Parovichnikova EN; National Medical Research Center for Hematology., Fomina DS; Sechenov First Moscow State Medical University (Sechenov University).; City Clinical Hospital №52., Frolova NF; City Clinical Hospital №52.; Yevdokimov Moscow State University of Medicine and Dentistry., Shevchenko AO; Sechenov First Moscow State Medical University (Sechenov University).; Pirogov Russian National Research Medical University.; Shumakov National Medical Research Center for Transplantology and Artificial Organs. |
| Jazyk: |
ruština |
| Zdroj: |
Terapevticheskii arkhiv [Ter Arkh] 2023 Oct 11; Vol. 95 (8), pp. 722-729. Date of Electronic Publication: 2023 Oct 11. |
| DOI: |
10.26442/00403660.2023.08.202391 |
| Abstrakt: |
On July 3, 2023, an interdisciplinary Council of Experts "The burden of COVID-19 in a heterogeneous population of immunocompromised patients - post-pandemic realities" was held in Moscow with leading experts in pulmonology, rheumatology, hematology, oncology, nephrology, allergology-immunology, transplantation, and infectious diseases. The aim of the meeting was to discuss the current clinical and epidemiologic situation related to COVID-19, the relevance of disease prevention strategies for high-risk patients. The experts addressed the following issues: 1) the disease burden of COVID-19 in 2023 for patients with immunodeficiency in different therapeutic areas; 2) the place of passive immunization with monoclonal antibodies as a method of COVID-19 prophylaxis among immunocompromised patients; 3) prerequisites for the inclusion of passive immunization of immunocompromised patients into routine clinical practice. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
